SEARCH
Flash-spelare saknas/Javascript är inte aktiverat

Welcome to Dilafor


Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity. 
The company has a balanced product portfolio representing some highly promising ideas and innovations in obstetrics. Each of our projects addresses an important and unmet medical need. 



All our drug development projects are based on Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH. 
One of them, Tafoxiparin is presently in development for the prevention and normalization of protracted labor. An exploratory Proof of Concept phase II clinical study comprising a total of 263 women has been completed.The drug was shown to be safe and well tolerated, and analyses of the results indicate that treatment with tafoxiparin can provide beneficial effects.


Most important, the results of the study gave Dilafor a solid base to plan in detail the further and ongoing clinical development program for a number of indications within the obstetric field.


 



Technologies & Discovery
Learn more about drug development at Dilafor.
Obstetrics
Learn more about our work in obstetrics.
NEWS
2014-02-20
Dilafor enters into a license and partnership agreement with Lee’s Pharmaceutical
>>
2013-11-25
Dilafor is among the hottest Life Science companies in the Stockholm-Uppsala region.
>>
2012-02-21
Ny metod kan lindra förlossning
Article published in Svenska Dagbladet February 20th 2012.
>>

Copyright © 2001-2014. All rights reserved.